For Imaging Centers and Health Systems

$650 per scan.
Zero new workflow.

LungAI adds a malignancy risk score to every eligible nodule on your existing LDCT reads, billed under CPT 0721T. It integrates directly into your CADe workflow, shifts diagnosis to earlier stages, and keeps downstream referrals inside your system.

Partner with Us Request a Demo
$650+
Revenue per scan via CPT 0721T
0.96 AUROC
AI nodule identification accuracy
85%
Of lung cancers found at late stage today
LungAI · CADe Integration
AI Active
Lung LDCT scan
3
Part-solid · Baseline
15.6 (4.1) mm   1,457 (31) mm³
Malignancy Risk Score: 87%
Workflow:
CADe Native
FDA 510(k) Pathway
The Market Reality

82% of Eligible Patients Never Get Scanned

Your CT scanner has capacity. The patients exist. The reimbursement code is active. The gap is identification, navigation, and a diagnostic AI that reduces the false positives eroding radiologist confidence.

85%
Diagnosed at late stage
5-year survival drops to <9% at Stage IV, compared to 77–92% at Stage I. Every missed screen is a missed early catch.
18%
Of eligible patients are screened
20 - 25M million Americans qualify for annual LDCT. Most are never identified. Oatmeal Health finds them and sends them to you.
18–40%
Lung-RADS false positive rate
Unnecessary callbacks erode radiologist trust and patient confidence. LungAI cuts false positives by 33–50% at equivalent sensitivity.
The Stage Shift Argument

Earlier Detection Keeps Patients and Revenue in Your System

Every stage shift from IV to I saves a patient's life and cuts treatment costs by 4-6x. LungAI is designed to catch cancers while they're still surgical, the outcome that benefits patients and health systems equally.

Stage 5-year survival Est. life-months Cost multiplier Est. lifetime cost What this means
Stage I 70–90% ~60 months 1x (baseline) ~$200K Surgery + monitoring. Best outcome. LungAI target
Stage II 50–60% ~48 months 1.55x ~$310K More aggressive treatment. Chemo likely
Stage III 20–40% ~30 months 2.41x ~$480K Radiation + chemo + possible surgery
Stage IV 6–10% ~18 months 4–6x ~$800K–$1.2M Palliative focus. Immunotherapy. 85% diagnosed here
For a health system treating 100 lung cancer cases: shifting from Stage IV to Stage I detection saves an estimated $60M–$100M in treatment costs, while keeping those patients in your system for follow-up imaging and monitoring for years.
Three Revenue Streams

One Integration. Three Ways to Grow.

Oatmeal Health fills your scanner with referred patients, adds a billable AI read to every eligible LDCT, and keeps downstream biopsy and oncology referrals inside your system.

More
Scan volume
We refer the patients

Oatmeal's FQHC referral pipeline identifies eligible patients and drives them to your imaging center. No new marketing spend, no new equipment.

AI identifies 20-pack-year history patients 9x faster than manual chart review
91% scan agreement rate from shared decision-making visits
Annual re-screening drives repeat volume year after year
~$650
Per scan, CPT 0721T
New revenue on existing scans

LungAI adds a billable AI malignancy risk score to every eligible LDCT you already perform. The reading radiologist or pulmonologist bills directly under CPT 0721T.

Integrates into your existing CADe workflow
Covered by Medicare and major commercial insurers
Companion code CPT 0722T also available
In-system
Downstream referrals
Keep revenue in your network

LungAI's risk ranking prioritizes high-confidence malignancies for follow-up. Biopsy, PET-CT, and oncology referrals flow to your specialists, not competitors.

33–50% fewer false positive callbacks means fewer unnecessary procedures
High-confidence cases get acted on faster, improving time to treatment
Positions your center as a lung cancer center of excellence
For Radiologists

A Second Opinion That Fits in Your Existing Read

LungAI appears inside your current CADe viewer, next to the nodule you're already looking at. No new login, no new screen, just a 0–100 malignancy score and a billable PDF report in under 3 minutes.

For Radiologists
Built for how you already read

LungAI doesn't add a new screen, a new login, or a new step. The malignancy score appears directly next to each nodule's characteristics in your existing CADe viewer. You review the score, you make the decision.

<3 min
Average read time
33%
Fewer false positive callbacks
0.96
AUROC, NLST test set
$650
Billable per read, CPT 0721T
Score appears in your CADe viewer
The 0–100 malignancy score displays directly next to each nodule's characteristics inside your existing CADe platform. No new application to open.
Augments Lung-RADS, doesn't replace it
Use your Lung-RADS classification for guideline-concordant documentation. Use the LungAI score as a quantitative second opinion on borderline cases.
Accounts for nodule type, history, and prior scan
Solid, part-solid, and GGO nodules are scored differently. Patient age, sex, and pack-years are explicit model inputs. Prior LDCT is registered automatically when available.
Documented, billable second opinion
A PDF report with per-nodule score and probability curve is delivered inside PACS for documentation and CPT 0721T billing.
For Pulmonologists

A Number You Can Rank Your Nodule Backlog By

Lung-RADS gives you a category. LungAI gives you a continuous 0 to 100 score so you can triage within Lung-RADS 3 and 4A, down-triage low-risk indeterminate nodules, and get the right patients into your limited appointment slots first.

Prioritize who needs 3-month vs 6-month follow-up
LungAI's continuous score gives you finer ranking within Lung-RADS 3 and 4A, where clinical uncertainty is highest and appointment slots are most limited.
Reduce unnecessary bronchoscopies
A low LungAI score on an indeterminate nodule gives you quantitative support for a watchful waiting decision, reducing invasive procedures on benign lesions.
Longitudinal tracking built in
Prior LDCT is registered automatically. The score accounts for interval change without manual scan comparison.
Patient-specific, not population-based
A 6mm nodule in a 72-year-old 40 pack-year smoker is not the same clinical question as the same nodule in a 51-year-old. LungAI scores them differently.
For Pulmonologists
Risk-rank your nodule backlog

You have a growing list of indeterminate nodules and limited appointment slots. Lung-RADS gives you a category. LungAI gives you a number you can rank by, so the patients who need you most get seen first.

Decision support only. LungAI does not automate diagnosis or recommend treatment. The pulmonologist reviews the score and makes the clinical decision.
Ready to Deploy

Already in Your Network.
The Reimbursement Path Exists Today.

LungAI integrates into your existing CADe and PACS infrastructure with no IT project and no new hardware. CPT 0721T is already covered by Medicare and major commercial insurers.

Already embedded in your network
Integration
No integration needed
If your health system uses Coreline aView LCS or other major CADe software, you are already in the network.
Works with any CADe or PACS
Compatible with GE, Philips, and Siemens scanners and any PACS or CADe software. Available as cloud or Docker on-premise.
Zero burden on your IT team
HIPAA-secure deployment via your existing CADe integration. No new hardware, no new project, no added burden on radiology staff.
The reimbursement path exists today
Regulatory and Reimbursement
CPT 0721T: ~$650 per scan. CMS-priced AI-specific quantitative image analysis code. Covered by Medicare and major commercial insurers today.
510(k) Pre-Submission filed March 2026. Pivotal study at Mass General Brigham launching Q2 2026. FDA clearance target Q2 2027.
HEDIS quality mandate. Lung screening may become the 4th HEDIS quality measure, creating payer pressure to drive screening volume.
H.R. 1406. The Lung Cancer Screening and Prevention Act expands Medicare coverage of FDA-cleared screening tests.
From the CEO of Coreline Soft

A Partnership Built Around Real Patients and Real Revenue

Coreline Soft, the CADe platform embedded in health systems nationwide, chose Oatmeal Health as its AI partner for lung cancer CADX Diagnostics.

"Our collaboration with Oatmeal Health extends beyond technology partnerships to secure insurance reimbursement-based revenue structures for actual US patients and establish leading technology in the lung cancer screening market. This demonstrates how AI diagnostic technology evolution can drive screening reimbursement structures, improved healthcare accessibility, and revenue model innovation."
KJ
Kim Jin-kook
CEO, Coreline Soft
For Imaging Centers and Health Systems

Ready to Put LungAI to Work in Your Center?

Whether you want to see it in your CADe viewer or build a full lung screening program, the next step takes less than 30 minutes.

For Radiologists and Department Heads
See LungAI in your workflow

Request a live demo showing how LungAI appears inside your CADe viewer, what the score looks like per nodule, and how the PDF report is delivered into PACS. Less than 30 minutes.

Request a workflow demo
For Imaging Program Leaders and CMOs
Build a lung screening program

Talk to our partnerships team about how Oatmeal Health drives scan referrals to your center, integrates LungAI into your CADe workflow, and enables your radiologists to bill CPT 0721T on eligible scans.

Talk to our team